JP2017507937A - ガン標的化il−12免疫療法 - Google Patents
ガン標的化il−12免疫療法 Download PDFInfo
- Publication number
- JP2017507937A JP2017507937A JP2016552988A JP2016552988A JP2017507937A JP 2017507937 A JP2017507937 A JP 2017507937A JP 2016552988 A JP2016552988 A JP 2016552988A JP 2016552988 A JP2016552988 A JP 2016552988A JP 2017507937 A JP2017507937 A JP 2017507937A
- Authority
- JP
- Japan
- Prior art keywords
- tumor
- targeted
- cancer
- cells
- nhs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2046—IL-7
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/246—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A61K2039/55533—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A61K2039/55538—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (18)
- 患者のガン疾患に対する免疫応答を誘導すること及び/又は刺激することによる、ガン治療に使用するための腫瘍標的化IL12であって、ここで、前記誘導又は刺激が、
前記薬剤によって引き起こされる
(i)ガン細胞の老化、及び/又は
(ii)ガン細胞又はガン組織の、起源の細胞又は組織への寛解、
を惹起し、
ここで、前記腫瘍標的化IL12が、腫瘍壊死中に曝露されたヒトDNAヒストンH1複合体に特異的であり、かつ、IL12にそのC末端を介して融合された、治療的に有効なモノクローナル抗体又は生物学的に活性があるその一部である、腫瘍標的化IL12。 - ガン疾患を患う患者において、ガン疾患に対する免疫反応を誘導する及び/又は刺激するための免疫調節性及び/又は免疫補完的薬剤を用いた併用療法に使用するための腫瘍標的化IL12であって、ここで、前記誘導又は刺激が、
前記薬剤によって引き起こされる
(i)ガン細胞の老化又は増殖停止、及び/又は
(ii)ガン細胞又はガン組織の、起源の細胞又は組織への寛解、
を惹起し、
ここで、前記腫瘍標的化IL12が、腫瘍壊死中に曝露されたヒトDNAヒストンH1複合体に特異的であり、かつ、IL12にそのC末端を介して融合された、治療的に有効なモノクローナル抗体又は生物学的に活性があるその一部である、腫瘍標的化IL12。 - 免疫調節性及び/又は免疫補完的薬剤が、インターロイキンファミリーから選択されるサイトカインである、請求項2に記載の使用のための腫瘍標的化IL12。
- 前記サイトカインが、IL−2及び/又はIL−7又はその誘導体である、請求項3に記載の使用のための腫瘍標的化IL12。
- IL−2及びIL−7が、ネイキッド形態(naked form)、共有結合形態、又は複合体形態で使用される、請求項4に記載の使用のための腫瘍標的化IL12。
- 前記IL−2又はIL−7が、免疫グロブリン重鎖又はその一部、例えばFc部分に共有結合的に融合された、又は抗IL−2抗体と複合体を形成する、請求項5に記載の使用のための腫瘍標的化IL12。
- 前記ガン細胞の老化が、前記薬剤によってトリガされた患者の免疫系の一連の前記刺激又は誘導において、内在性のIFNγ及び/又はTNFを生成することによって引き起こされる、請求項1〜6のいずれか1項に記載の使用のための腫瘍標的化IL12。
- 前記ガン細胞の老化が、安定した増殖停止をもたらす、請求項1〜7のいずれか1項に記載の使用のための腫瘍標的化IL12。
- 前記ガン細胞の老化が、直接的な免疫特異的細胞傷害性効果とは独立している、請求項1〜8のいずれか1項に記載の使用のための腫瘍標的化IL12。
- 前記ガン疾患が、固形腫瘍、又は筋肉、骨、神経、軟骨、腱、血管、及び脂肪若しくは線維組織の腫瘍に関連する、請求項1〜9のいずれか1項に記載の使用のための腫瘍標的化IL12。
- 前記ガンが肉腫である、請求項10に記載の使用のための腫瘍標的化IL12。
- 前記治療が、筋形成分化の誘導を惹起する、請求項10又は11に記載の使用のための腫瘍標的化IL12。
- 放射線療法又は放射線−化学療法と併用する、請求項1〜12のいずれか1項に記載の使用のための腫瘍標的化IL12。
- 前記IL−12が、そのp40及び/又はp30サブユニットのN末端を介して、抗体又は生物学的に有効なその一部のC末端へ融合されている、請求項1〜13のいずれか1項に記載の使用のための腫瘍標的化IL12。
- 前記抗体が、完全ヒトNHS76抗体であり、NHS−IL12と命名されている、請求項1〜14のいずれか1項に記載の使用のための腫瘍標的化IL12。
- (i)腫瘍壊死中に曝露されたヒトDNA−ヒストンH1複合体に特異的であり、かつ、IL12のp40及び/又はp30サブユニットのN末端にそのC末端を介して融合された、完全ヒトモノクローナル抗体NHS76を含む第一パッケージ、及び
(ii)ガン疾患に対する免疫反応を誘導する及び/又は刺激するための免疫調節性及び/又は免疫補完的薬剤を含む第二パッケージ
を含む、医薬キット。 - 免疫調節性薬剤がサイトカインである、請求項16に記載の医薬キット。
- 免疫調節性性サイトカインが、ネイキッド形態、共有結合形態、又は複合体形態のIL−2又はIL−7である、請求項17に記載の医薬キット。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14000585 | 2014-02-19 | ||
EP14000585.1 | 2014-02-19 | ||
PCT/EP2015/000363 WO2015124297A1 (en) | 2014-02-19 | 2015-02-18 | Cancer-targeted il-12 immunotherapy |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2017507937A true JP2017507937A (ja) | 2017-03-23 |
JP2017507937A5 JP2017507937A5 (ja) | 2017-09-07 |
JP6416926B2 JP6416926B2 (ja) | 2018-10-31 |
Family
ID=50151085
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016552988A Active JP6416926B2 (ja) | 2014-02-19 | 2015-02-18 | ガン標的化il−12免疫療法 |
Country Status (12)
Country | Link |
---|---|
US (1) | US20170166620A1 (ja) |
EP (1) | EP3107573B1 (ja) |
JP (1) | JP6416926B2 (ja) |
KR (2) | KR20230027322A (ja) |
CN (1) | CN105992590B (ja) |
AU (1) | AU2015221181B2 (ja) |
CA (1) | CA2940018C (ja) |
ES (1) | ES2703826T3 (ja) |
MX (1) | MX2016010674A (ja) |
PT (1) | PT3107573T (ja) |
RU (1) | RU2689160C2 (ja) |
WO (1) | WO2015124297A1 (ja) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10888594B2 (en) * | 2016-05-30 | 2021-01-12 | National University Corporation Tottori University | Genetically engineered vaccinia viruses |
US20190336552A1 (en) | 2016-05-30 | 2019-11-07 | Astellas Pharma Inc. | Genetically engineered vaccinia viruses |
KR102658660B1 (ko) * | 2017-01-23 | 2024-04-17 | 크라제 메디컬 씨오 리미티드 | Bcma 표적 항체 및 이의 용도 |
CN108686202A (zh) * | 2017-04-06 | 2018-10-23 | 张晋宇 | 肿瘤免疫疗法 |
EP3661954B1 (en) | 2017-08-03 | 2022-02-09 | Amgen Inc. | Interleukin-21 muteins and methods of treatment |
ES2928576T3 (es) | 2017-09-08 | 2022-11-21 | Amgen Inc | Inhibidores de KRAS G12C y métodos de uso de los mismos |
CR20210319A (es) | 2018-01-12 | 2021-07-27 | Amgen Inc | ANTICUERPOS ANTI-PD-1 Y MÉTODOS DE TRATAMIENTO (Div. 2020-330) |
CN110396133B (zh) * | 2018-04-25 | 2021-07-23 | 免疫靶向有限公司 | 一种以白介素12为活性成分的融合蛋白型药物前体 |
CN112513276B (zh) * | 2018-07-30 | 2024-03-15 | 张晋宇 | 蛋白质异二聚体及其用途 |
WO2020051363A1 (en) * | 2018-09-07 | 2020-03-12 | Nantbio, Inc. | Targeted il-12 treatments and methods to stimulate hank and nk92mi cells |
SG11202103097QA (en) | 2018-09-26 | 2021-04-29 | Astellas Pharma Inc | Cancer therapy by combination use of oncolytic vaccinia virus and immune checkpoint inhibitor, and pharmaceutical composition and combination medicine for use in the cancer therapy |
CN111848810A (zh) * | 2019-04-28 | 2020-10-30 | 张晋宇 | 一种蛋白质分子及其用途 |
WO2021232200A1 (en) * | 2020-05-18 | 2021-11-25 | Guangdong Tcrcure Biopharma Technology Co., Ltd. | Il-12 armored immune cell therapy and uses thereof |
WO2024086739A1 (en) * | 2022-10-20 | 2024-04-25 | Synthekine, Inc. | Methods and compositions of il12 muteins and il2 muteins |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012506394A (ja) * | 2008-10-21 | 2012-03-15 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 放射線および免疫サイトカインによる癌治療 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004074437A2 (en) * | 2003-02-14 | 2004-09-02 | University Of Southern California | Compositions and methods for cancer immunotherapy |
EP1874818B1 (en) * | 2005-04-22 | 2011-04-13 | Eli Lilly And Company | Tgf beta 1 specific antibodies |
ATE555125T1 (de) * | 2005-12-30 | 2012-05-15 | Merck Patent Gmbh | Interleukin-12p40-varianten mit verbesserter stabilität |
US20160279213A1 (en) * | 2013-12-16 | 2016-09-29 | Merck Patent Gmbh | Survivin-Directed Cancer Vaccine Therapy |
-
2015
- 2015-02-18 KR KR1020237005155A patent/KR20230027322A/ko not_active Application Discontinuation
- 2015-02-18 MX MX2016010674A patent/MX2016010674A/es unknown
- 2015-02-18 AU AU2015221181A patent/AU2015221181B2/en active Active
- 2015-02-18 CA CA2940018A patent/CA2940018C/en active Active
- 2015-02-18 WO PCT/EP2015/000363 patent/WO2015124297A1/en active Application Filing
- 2015-02-18 EP EP15705772.0A patent/EP3107573B1/en active Active
- 2015-02-18 RU RU2016136990A patent/RU2689160C2/ru active
- 2015-02-18 JP JP2016552988A patent/JP6416926B2/ja active Active
- 2015-02-18 ES ES15705772T patent/ES2703826T3/es active Active
- 2015-02-18 PT PT15705772T patent/PT3107573T/pt unknown
- 2015-02-18 US US15/119,882 patent/US20170166620A1/en not_active Abandoned
- 2015-02-18 KR KR1020167025301A patent/KR20160120335A/ko not_active IP Right Cessation
- 2015-02-18 CN CN201580009643.5A patent/CN105992590B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012506394A (ja) * | 2008-10-21 | 2012-03-15 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 放射線および免疫サイトカインによる癌治療 |
Non-Patent Citations (1)
Title |
---|
CRAIG B DAVIS, CANCER IMMUNOL IMMUNOTHER, vol. Vol.52, JPN6017036104, 2003, pages 297 - 308 * |
Also Published As
Publication number | Publication date |
---|---|
EP3107573B1 (en) | 2018-09-26 |
RU2016136990A (ru) | 2018-03-22 |
JP6416926B2 (ja) | 2018-10-31 |
WO2015124297A1 (en) | 2015-08-27 |
US20170166620A1 (en) | 2017-06-15 |
AU2015221181A1 (en) | 2016-09-29 |
CN105992590B (zh) | 2019-12-31 |
RU2689160C2 (ru) | 2019-05-24 |
CN105992590A (zh) | 2016-10-05 |
ES2703826T3 (es) | 2019-03-12 |
AU2015221181B2 (en) | 2020-08-20 |
CA2940018C (en) | 2018-12-04 |
MX2016010674A (es) | 2016-11-08 |
RU2016136990A3 (ja) | 2018-10-10 |
EP3107573A1 (en) | 2016-12-28 |
KR20230027322A (ko) | 2023-02-27 |
CA2940018A1 (en) | 2015-08-27 |
KR20160120335A (ko) | 2016-10-17 |
PT3107573T (pt) | 2019-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6416926B2 (ja) | ガン標的化il−12免疫療法 | |
Maggs et al. | CAR T cell-based immunotherapy for the treatment of glioblastoma | |
Slaney et al. | Dual-specific chimeric antigen receptor T cells and an indirect vaccine eradicate a variety of large solid tumors in an immunocompetent, self-antigen setting | |
JP6954648B2 (ja) | 併用療法による固形腫瘍又はリンパ系腫瘍の治療方法 | |
Chuntova et al. | Genetically engineered T-cells for malignant glioma: overcoming the barriers to effective immunotherapy | |
JP2021191790A (ja) | 併用療法によって固形腫瘍又はリンパ系腫瘍を処置する方法 | |
KR20220068240A (ko) | 암 치료를 위한 암 요법과 사이토카인 조절 요법의 조합 | |
KR20170015460A (ko) | 방사선 치료와 조합된 pd-1 및 pd-l1에 대한 길항제를 이용하는 암 치료 방법 | |
Mazzolini et al. | Gene therapy of cancer with interleukin-12 | |
Palata et al. | Radiotherapy in combination with cytokine treatment | |
KR20180030879A (ko) | 복막암을 치료하기 위한 조성물 및 방법 | |
Alaniz et al. | Low molecular weight hyaluronan preconditioning of tumor-pulsed dendritic cells increases their migratory ability and induces immunity against murine colorectal carcinoma | |
Wu et al. | Radio-immunotherapy and chemo-immunotherapy as a novel treatment paradigm in malignant pleural mesothelioma | |
Pieper et al. | Radiation augments the local anti-tumor effect of in situ vaccine with CpG-oligodeoxynucleotides and anti-OX40 in immunologically cold tumor models | |
US10155024B2 (en) | Composition for preventing or treating B-cell lymphoma comprising IL-21 expressing mesenchymal stem cells | |
US20150307614A1 (en) | Enhanced immunological responses | |
AU2020252569A1 (en) | Method for enhancing cellular immunotherapy | |
US20210169937A1 (en) | Method for the treatment of a tumor patient with adoptive t cell immunotherapy | |
Madany et al. | Immunobiology and immunotherapeutic targeting of glioma stem cells | |
Aghajani et al. | Current approaches in glioblastoma multiforme immunotherapy | |
US20110135637A1 (en) | Trimodal cancer therapy | |
Bella-Carreño | Evaluation of Modified Vaccinia virus Ankara based locoregional immunotherapy in peritoneal carcinomatosis models | |
Chuntova et al. | Genetically Engineered T-Cells for Malignant Glioma: Overcoming the Barriers to | |
CN115052973A (zh) | 用于产生细胞毒性效应子记忆t细胞以用于癌症的t细胞治疗的方法 | |
Murphy et al. | and Fas Ligand Are Required for γ IFN |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20170913 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170926 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171226 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180508 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180625 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180904 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20181004 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6416926 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |